Key result
Cangrelor monotherapy enables perioperative bridging in high bleeding risk patients with recent PCI.
Why the study?
Perioperative management of DAPT is challenging, particularly in patients with recent PCI where intravenous antiplatelet agents are recommended.
Case Report (n=2)
Cangrelor monotherapy can be utilized for perioperative bridging in high bleeding risk patients with recent PCI undergoing surgery.
May support cangrelor bridging consideration in select high-bleeding-risk post-PCI patients; hypothesis-generating case report requiring prospective validation.
Managing dual antiplatelet therapy (DAPT) perioperatively is challenging, especially in patients who have recently undergone percutaneous coronary intervention (PCI). Intravenous antiplatelet agents are recommended in these cases. This case series describes the perioperative management of two high bleeding risk patients with recent PCI undergoing cardiac and non-cardiac surgeries using cangrelor monotherapy.
No takes yet. Share an insight, caveat, or question.
Spyridon-Filippos Papadopoulos (2025) conducted a case report in Recent percutaneous coronary intervention (PCI) (n=2). Cangrelor monotherapy was evaluated. Cangrelor monotherapy was used for perioperative bridging in two high bleeding risk patients with recent PCI undergoing cardiac and non-cardiac surgeries.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: